Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | GLA | P06280 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | RAB9A | P51151 | 4/20 | 0.58 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30008156 | 0.81 | RAB9A (0.67) | L3MBTL1MAPK1NPC1GLASMN1; SMN2 | |
| SCHEMBL14788895 | 0.81 | TSHR (0.56) | L3MBTL1MAPK1NPC1GLARAB9A | |
| SCHEMBL24843516 | 0.80 | NPC1 (0.47) | L3MBTL1MAPK1NPC1GLASMN1; SMN2 | |
| SCHEMBL15527734 | 0.80 | L3MBTL1 (0.51) | L3MBTL1MAPK1NPC1GLASMN1; SMN2 | |
| SCHEMBL30008478 | 0.80 | L3MBTL1 (0.91) | L3MBTL1MAPK1NPC1GLASMN1; SMN2 | |
| SCHEMBL29791335 | 0.79 | L3MBTL1 (0.51) | L3MBTL1MAPK1NPC1GLASMN1; SMN2 | |
| SCHEMBL1848793 | 0.78 | L3MBTL1 (0.61) | L3MBTL1MAPK1NPC1GLASMN1; SMN2 | |
| SCHEMBL27902865 | 0.77 | TDP1 (0.45) | L3MBTL1MAPK1NPC1GLARAB9A | |
| SCHEMBL1849856 | 0.75 | SMN1; SMN2 (0.73) | L3MBTL1MAPK1NPC1GLASMN1; SMN2 | |
| SCHEMBL28838814 | 0.75 | L3MBTL1 (0.64) | L3MBTL1MAPK1NPC1GLASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402875-A1 | S1P3 Antagonists | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2022-12-22 | — | — | US | disclosed |
| US-11472772-B2 | S1P3 antagonists | TEVA PHARMACEUTICAL INDUSTRIES LIMITED (IL) | 2022-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402875-A1 | S1P3 Antagonists | S1PR3, S1PR5, S1PR1 | L3MBTL1 4523/4885MAPK1 2589/4885NPC1 292/4885 |
| US-11472772-B2 | S1P3 antagonists | S1PR3, S1PR5, S1PR1 | L3MBTL1 4523/4885MAPK1 2589/4885NPC1 292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.